HRMY Harmony Biosciences Holdings
Company Analysis
Latest News
Harmony Biosciences Shares Fall on Profit-Taking After Pediatric WAKIX Approval
The U.S. Food and Drug Administration approved WAKIX to treat excessive daytime sleepiness in children aged six and older with narcolepsy, expanding the drug’s...
Deutsche Bank Lifts Harmony Biosciences Target as Wakix Patent Fight Tips in the Company's Favor — But Is $42 Already the Ceiling?
Shares of Harmony Biosciences surged 6.1% to $41.98 in pre-market trading October 2, nearly touching the new Deutsche Bank price target of $42, after the bank...
🟢 Harmony Biosciences is trading 6.1% up in pre-market after Deutsche Bank raised its target to $42
Harmony Biosciences is trading 6.09% up at $41.98 in pre-market on October 2, versus the October 1 close of $39.57, after Deutsche Bank raised its price target...
🔴 Harmony Biosciences is trading 4.1% down today amid market-wide risk-off pressure
Harmony Biosciences is trading 4.05% down at $39.59 on September 28, 2026; broader market risk-off pressure is the clearest available context, though no direct...
Harmony Biosciences Bolsters WAKIX Patent Defense, Delaying Generic Entry Until 2030
Oppenheimer reiterated an Outperform rating and $70.00 price target for Harmony Biosciences. The company filed a new patent complaint against a generic...
🔴 Harmony Biosciences is trading 5.4% down in pre-market amid weaker futures and elevated Treasury yields
Harmony Biosciences is trading 5.4% down in pre-market at $38.30, with the decline appearing aligned with broader risk-off conditions, including weaker U.S....
🔴 Harmony Biosciences is trading 4.09% down today amid biotech-sector weakness
Harmony Biosciences is trading at $39.83, down 4.09%, with the decline appearing primarily tied to biotechnology-sector weakness. - No clear company-specific...
🟢 Harmony Biosciences is trading 1.7% up in pre-market amid broad market strength
Harmony Biosciences is trading 1.7% up at $42.75 in pre-market, with the move appearing most consistent with positive broader market sentiment rather than a...
🔴 Harmony Biosciences is trading 0% down in pre-market with no specific catalyst identified
Harmony Biosciences is trading at $42.02 (0%), with no meaningful pre-market change versus the September 18 close. - No fresh September 21 company-specific...
🔴 Harmony Biosciences is trading 6.4% down in pre-market — catalyst remains unclear
Harmony Biosciences is trading 6.4% down at $39.50 after no clear company-specific announcement was identified for September 17, 2026. - Recent company...
🟢 Harmony Biosciences is trading 4.06% up today despite biotech stocks falling 4.24%
Harmony Biosciences is trading 4.06% up now at $40.98, despite broad market weakness and a 4.24% decline in biotechnology stocks. - No clear company-specific...
🔴 Harmony Biosciences is trading 4.1% down in pre-market today as biotech stocks retreat
Harmony Biosciences is trading 4.1% down now at $36.50, primarily amid a biotech-sector pullback following the Moderna-fueled rally. - The stock closed at...
🔴 Harmony Biosciences falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Harmony Biosciences Upgraded to Strong Buy, Following Record Q2 Earnings Beat
Wall Street Zen upgraded Harmony Biosciences to a strong-buy rating on August 16, 2026. The move follows the company’s record-breaking second-quarter financial...
Harmony Biosciences Posts a Blowout Quarter, But Can a One-Drug Company Justify Its Run Toward Billion-Dollar Revenue?
Shares of Harmony Biosciences surged 11.2% to $39.58 after the rare-disease drugmaker delivered a record second quarter that blew past Wall Street expectations...
🟢 Harmony Biosciences is trading 11.5% up today on record Q2 results and reaffirmed full-year guidance
Harmony Biosciences is trading 11.5% up at $39.58 after reporting record Q2 2026 results driven by strong demand for WAKIX. • Revenue for the quarter grew 30%...
Harmony Biosciences' second quarter revenue grew 30% to $261.3M, beating estimates while the company reiterates FY26 guidance.
Harmony Biosciences reported record second quarter 2026 net revenue of $261.3 million, a 30% increase year-over-year, driven by continued strong demand for...
🟢 Harmony Biosciences is trading 4.4% up today ahead of Q2 earnings report
Harmony Biosciences is trading at $37.17 (up 4.4%) in pre-market, extending its recent upward trend as investors position ahead of the company’s Q2 2026...
Harmony Biosciences Holdings Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Harmony Biosciences is projected to report Q2 2026 revenue of $249.0 million and EPS of $0.97, with the stock’s current price of $35.24 trading well below the...
🔴 Harmony Biosciences is trading 5.3% down
Harmony Biosciences is trading at $34.90, down 5.3% from a comparison close of $36.84 during regular trading. This is a price-action follow-up, so a separate...